Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Are Value-Based Arrangements the Answer We've Been Waiting for?

Tytuł:
Are Value-Based Arrangements the Answer We've Been Waiting for?
Autorzy:
Dubois RW; National Pharmaceutical Council, Washington, DC, USA.
Westrich K; National Pharmaceutical Council, Washington, DC, USA. Electronic address: .
Buelt L; National Pharmaceutical Council, Washington, DC, USA.
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2020 Apr; Vol. 23 (4), pp. 418-420. Date of Electronic Publication: 2020 Feb 28.
Typ publikacji:
Editorial
Język:
English
Imprint Name(s):
Publication: Jan./Feb. 2011- : New York : Elsevier
Original Publication: Malden, MA : Blackwell Science, c1998-
MeSH Terms:
Health Care Costs*
Contracts/*economics
Delivery of Health Care/*economics
Value-Based Purchasing/*economics
Cost Control ; Humans ; United States
Contributed Indexing:
Keywords: health spending; pharmaceuticals; value; value-based arrangements
Entry Date(s):
Date Created: 20200425 Date Completed: 20200811 Latest Revision: 20200811
Update Code:
20240105
DOI:
10.1016/j.jval.2019.10.016
PMID:
32327157
Opinia redakcyjna
In response to rising healthcare costs, value-based arrangements (VBAs) have emerged as a mechanism for transforming how we pay for high-cost therapies. As we think about how VBAs fit into the larger effort of the United States healthcare system to transition to value-based payment, it is important to consider the strengths and limitations associated with this model and to set appropriate expectations for what VBAs can realistically achieve. For example, for VBAs to meaningfully affect overall healthcare spending, there needs to be a sufficient number of products that meet the ideal criteria for a value-based contract. These products also need to represent a meaningful share of healthcare spending, and the VBA contracts need to be designed with enough financial risk to actually influence spending. Although there are limited data about the components of current contracts (eg, how much financial risk is involved, product and class specifications), VBAs will likely not be a singular solution for improving healthcare cost containment. Instead, VBAs offer an opportunity for the US healthcare system to achieve higher value for dollars spent when implemented in combination with other value-based payment mechanisms and policies that disincentivize low-value care.
(Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies